Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 70,700 shares, a growth of 644.2% from the August 15th total of 9,500 shares. Based on an average trading volume of 249,000 shares, the days-to-cover ratio is currently 0.3 days.
Bioxytran Stock Up 18.8 %
BIXT stock opened at $0.19 on Thursday. The business’s 50-day moving average is $0.17 and its two-hundred day moving average is $0.31. Bioxytran has a 1 year low of $0.12 and a 1 year high of $1.15.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last posted its quarterly earnings results on Monday, July 31st. The company reported ($0.01) EPS for the quarter. On average, equities research analysts predict that Bioxytran will post -0.02 EPS for the current fiscal year.
Bioxytran Company Profile
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Featured Stories
- Five stocks we like better than Bioxytran
- Breakout Stocks: What They Are and How to Identify Them
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- How to Invest in Electric Cars
- 3 Low-Cost ETFs That Are Crushing SPY
- The How and Why of Investing in Biotech Stocks
- Shutterstock is the Value Stock they don’t want you to know about
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
